HTLV-2 infection
disease diseaseOn this page
Also known as HTLV II INFECTHTLV-II InfectionHTLV-II InfectionsHuman T lymphotropic Virus 2 InfectionHuman T lymphotropic Virus 2 InfectionsHuman T-lymphotropic Virus 2 InfectionHuman T-lymphotropic Virus 2 InfectionsINFECT HTLV IIInfection, HTLV-IIInfections, HTLV IIInfections, HTLV-II
Summary
HTLV-2 infection (MONDO:0021183) is a disease and 3 clinical trials. A subtype of deltaretrovirus infections — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 3
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | HTLV-2 infection |
| Mondo ID | MONDO:0021183 |
| EFO | EFO:1001349 |
| MeSH | D015491 |
| SNOMED CT | 425740005 |
| UMLS | C0020102 |
| MedGen | 42515 |
| GARD | 0009783 |
| Is cancer (heuristic) | no |
Also known as: HTLV II INFECT · HTLV-2 infection · HTLV-II Infection · HTLV-II infection · HTLV-II Infections · Human T lymphotropic Virus 2 Infection · Human T lymphotropic Virus 2 Infections · Human T-lymphotropic Virus 2 Infection · Human T-lymphotropic virus 2 infection · Human T-lymphotropic Virus 2 Infections · INFECT HTLV II · Infection, HTLV-II · Infections, HTLV II · Infections, HTLV-II
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › deltaretrovirus infections › HTLV-2 infection
Related subtypes (1): adult T-cell leukemia/lymphoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 3.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 2 |
| PHASE4 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03226119 | PHASE4 | COMPLETED | MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study |
| NCT01467024 | Not specified | UNKNOWN | Evaluation of the MP Diagnostics HTLV Blot 2.4 |
| NCT03146013 | Not specified | COMPLETED | Dual Algorithm Post Market Clinical Study |
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.